NCT06833866 2026-04-17
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
The Methodist Hospital Research Institute
Phase 1 Recruiting
Clinical Trials
18 trialsNCT06625775 2026-04-13
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT06663319 2026-04-13
A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers
Janssen Research & Development, LLC
Phase 1 Recruiting
NCT04929223 2026-03-31
A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)
Hoffmann-La Roche
Phase 1 Recruiting
NCT07500298 2026-03-30
Phase 1 Study Of SAR445877 In Combination With FOLFOX6 And Bevacizumab As First-Line Treatment For Microsatellite Stable Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1 Not yet recruiting
NCT06917079 2026-03-23
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 1 Recruiting
NCT06179160 2026-03-16
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
Incyte Corporation
Phase 1 Recruiting
NCT06838338 2026-01-08
JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC
Peking University Cancer Hospital & Institute
Phase 1 Active not recruiting
NCT00873275 2025-06-22
Ursodiol, Combination Chemotherapy, and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer
City of Hope Medical Center
Phase 1 Completed
NCT03597581 2025-04-03
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
Inspirna, Inc.
Phase 1 Completed
NCT00059930 2025-03-26
Adjuvant Hepatic Arterial Infusion and Combination Chemotherapy in Treating Patients With Resectable Hepatic Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT02009449 2024-11-15
IVY
Eli Lilly and Company
Phase 1 Completed
NCT01420874 2023-05-06
Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
Barbara Ann Karmanos Cancer Institute
Phase 1 Completed
NCT00851136 2022-12-13
A Study of PRO95780 Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, and Metastatic Colorectal Cancer (APM4566g)
Genentech, Inc.
Phase 1 Completed
NCT03035253 2020-08-11
A Study of OMP-305B83 in Subjects With Metastatic Colorectal Cancer
Mereo BioPharma
Phase 1 Terminated
NCT00873756 2016-11-02
A Study of Dulanermin Administered in Combination With the FOLFOX Regimen and Bevacizumab in Patients With Previously Untreated, Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
Genentech, Inc.
Phase 1 Completed
NCT00599924 2015-07-15
Study Of Sunitinib Plus FOLFOX In Patients With Solid Tumors
Pfizer
Phase 1 Completed
NCT00008294 2013-01-18
Combination Chemotherapy in Treating Patients With Unresectable Liver Metastases From Colorectal Cancer
Memorial Sloan Kettering Cancer Center
Phase 1 Completed